Allergy-Focused Circassia Raises £60m, Led by Imperial Innovations
This article was originally published in The Pink Sheet Daily
Funding round is Europe's fifth-largest in over a decade, underscoring investor confidence in Circassia's T-cell vaccine technology.
You may also be interested in...
U.K. biotech Circassia has the first potential cat allergy vaccine to reach advanced clinical studies in Europe and the U.S., funded by a large round of VC financing completed in 2011. Its allergen-free technology could revolutionize the treatment of allergies.
The AIM-listed tech transfer group will increase its early-stage investments in spin-outs from Imperial College and three other top UK universities
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.